Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

Azacitidine 4Nivolumab 2sargramostim 1ruxolitinib 1rucaparib 1incomplete Freund's adjuvant 1cc-486 1bemcentinib 1abiraterone 1Tretinoin 1TTI-621 1Standard of Care 1Rituximab 1Radiotherapy 1Practice Guidelines as Topic 1Polymerase Chain Reaction 1Palliative Care 1Paclitaxel 1Methylprednisolone 1Melphalan 1Injections 1Immunoenzyme Techniques 1INCB059872 1INCB057643 1Gemcitabine 1Flow Cytometry 1Cyclosporine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × INCB059872 × Thoracic × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡